For instance, everolimus, an mTOR-inhibitor (mTORi), has been found particularly efficient for treating subependymal giant cell astrocytomas (SEGA), angiomyolipomas (AML), facial angiofibromas, and epilepsy in TSC patients, if used continuously [6–9]. Here, MTOR is linked to subependymal giant cell astrocytoma.